Pfizer is developing berobenatide, a monthly GLP-1 injection for obesity treatment, which has shown a side-effect profile similar to that of Wegovy in midstage clinical trials. Unlike current blockbuster drugs such as Wegovy and Eli Lilly’s Zepbound, which require weekly injections, berobenatide aims to provide a monthly dosing option. This development could offer patients a more convenient treatment regimen for weight management. The trial results indicate that the safety and tolerability of berobenatide are comparable to existing therapies, supporting its potential role in the obesity treatment landscape. The drugmaker aims for berobenatide to be the first monthly GLP-1 weight-loss injection, distinguishing it from blockbuster drugs like Wegovy and Eli Lilly’s Zepbound.